menu search

Tarsus to host webcast to review topline results from saturn-2 phase 3, the second pivotal trial of tp-03 for the treatment of demodex blepharitis

IRVINE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply pro...

April 29, 2022, 9:23 pm

Ocuphire pharma to present at wet amd & dme drug development summit in boston, ma

FARMINGTON HILLS, Mich., April 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ...

April 6, 2022, 8:00 am

Allergan shares topline data for twice daily vuity (pilocarpine) in blurry vision study

Allergan, an AbbVie Inc (NYSE: ABBV) company, announced topline data from Phase 3 VIRGO trial evaluating Vuity (pilocarpine HCl ...

April 5, 2022, 2:45 pm

Ocuphire pharma to present at oppenheimer annual healthcare conference

FARMINGTON HILLS, Mich., March 10, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ...

March 10, 2022, 9:27 am

Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barré syndrome and huntington's disease at aan 2022

BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi...

March 3, 2022, 4:01 pm

Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barré syndrome and huntington's disease at aan 2022

BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi...

March 3, 2022, 4:01 pm

Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barré syndrome and huntington's disease at aan 2022

BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi...

March 3, 2022, 4:01 pm

Skye bioscience reports positive results for sb-100 in glp toxicology study; phase i clinical trial expected in 2q 2022

Skye Bioscience inc (OTCQB:SKYE) announced that it has completed a good laboratory practice (GLP) nonclinical toxicology study of its SBI-100 ...

February 16, 2022, 9:19 am

Skye bioscience reports positive results for sb-100 in glp toxicology study; phase i clinical trial expected in 2q 2022

Skye Bioscience inc (OTCQB:SKYE) announced that it has completed a good laboratory practice (GLP) nonclinical toxicology study of its SBI-100 ...

February 16, 2022, 9:19 am

Skye bioscience reports positive results for sb-100 in glp toxicology study; phase i clinical trial expected in 2q 2022

Skye Bioscience inc (OTCQB:SKYE) announced that it has completed a good laboratory practice (GLP) nonclinical toxicology study of its SBI-100 ...

February 16, 2022, 9:19 am

Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...

October 11, 2021, 12:30 pm

Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...

October 11, 2021, 12:30 pm

Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...

October 11, 2021, 12:30 pm

Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...

October 11, 2021, 12:30 pm

Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...

October 11, 2021, 12:30 pm

Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...

October 11, 2021, 12:30 pm


Search within

Pages Search Results: